Impact of Implantation of an LAA Occluder on ANP and BNP Level and Quality of Life

Atrial Fibrillation Clinical Trial

Official title:

Impact of Implantation of an LAA Occluder on ANP and BNP Level and Quality of Life

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03085667
• Other study ID #: SMW 05
• Status: Completed
• Start date: January 2011
• Est. completion date: December 2015

Study information

• Verified date: March 2020
• Source: University of Leipzig
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Closure of the LAA by several devices is a alternative therapy to oral anticoagulation in patients with Atrail fibrillation. Nothing is known about the acute influence of a device closure of the LAA on the secretion of ANB nad BNP hormones. Therefore aim of our study is to measure ANB and BNP levvels before and after Implantation of an LAA closure device.

Description:

ANB and BNP levels are measured before, directly after and late after 24 h in central or periphereal venous blood from patients undergoing interventional LAA closure.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: December 2015
• Est. primary completion date: January 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patients undergoing LAA closure

Exclusion Criteria:

• none

Related Conditions & MeSH terms

• Atrial Fibrillation

Locations

Country	Name	City	State
Germany	Heart Center Leipzig- University Leipzig	Leipzig

Sponsors (1)

Lead Sponsor	Collaborator
University of Leipzig

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline atrial natriuretic Peptide (ANP)	comparison of ANP level pre and post intervention	24 h post intervention